Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Infectious Disorders - Drug Targets (Formerly Current Drug Targets - Infectious Disorders)
  4. Volume 25, Issue 2
  5. Article
Volume 25, Issue 2
  • ISSN: 1871-5265
  • E-ISSN: 2212-3989

Abstract

This article explores the Human Monkeypox Virus (MPV), a contagious virus that causes disease in both vertebrates and insects. It originated in Denmark in 1958 and expanded beyond Africa during the 1970s. The virus was initially detected in the United States in 2003 following the hospitalisation of a toddler who had been bitten by a prairie dog. The article examines the identification of the virus, its categorization into two genetic groups with different levels of harmfulness, and its genetic changes over time due to specific influences. Additionally, it investigates the immunological reaction to MPXV, encompassing both the innate and adaptive systems. This article also addresses the diagnostic difficulties presented by MPXV's resemblance to other orthopoxviruses and the progress made in molecular diagnostics. The paper analyses different therapeutic interventions, such as tecovirimat, an antiviral medication, and JYNNEOS, a vaccine, in terms of their efficacy, potential drawbacks, and the difficulties encountered in managing outbreaks. The future outlook emphasises the necessity of inventive research methodologies, worldwide monitoring, and individualised medical treatments to counteract the dissemination of MPXV and alleviate its consequences on public health.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/iddt/10.2174/0118715265309361240806064619
2024-08-16
2024-12-28

  • From This Site

    /content/journals/iddt/10.2174/0118715265309361240806064619
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. AnwarF. HaiderF. KhanS. Clinical manifestation, transmission, pathogenesis, and diagnosis of monkeypox virus: A comprehensive review.Life (Basel)202313252210.3390/life13020522 36836879
     [Google Scholar]
  2. KhattakS. Monkeypox virus preparation in Pakistan-Next viral zoonotic disease outbreak after COVID-19?Biom. Lett.20228219620110.47262/BL/8.2.20220610
     [Google Scholar]
  3. MagnusP. AndersenE.K. PetersenK.B. Birch-AndersenA. A pox-like disease in cynomolgus monkeys.Acta Pathol. Microbiol. Scand.195946215617610.1111/j.1699‑0463.1959.tb00328.x
     [Google Scholar]
  4. BungeE.M. HoetB. ChenL. The changing epidemiology of human monkeypox—A potential threat? A systematic review.PLoS Negl. Trop. Dis.2022162e001014110.1371/journal.pntd.0010141 35148313
     [Google Scholar]
  5. WHO. Mpox (monkeypox) outbreak.2022Available From: https://www.who.int/europe/emergencies/situations/monkeypox
  6. KhattakS. RaufM.A. AliY. The monkeypox diagnosis, treatments and prevention: A review.Front. Cell. Infect. Microbiol.202312108847110.3389/fcimb.2022.1088471 36814644
     [Google Scholar]
  7. HatamiH. JamshidiP. ArbabiM. Demographic, epidemiologic, and clinical characteristics of human monkeypox disease pre- and post-2022 outbreaks: A systematic review and meta-analysis.Biomedicines202311395710.3390/biomedicines11030957 36979936
     [Google Scholar]
  8. GüntherT. HaasL. AlawiM. Recovery of the first full-length genome sequence of a parapoxvirus directly from a clinical sample.Sci. Rep.201771373410.1038/s41598‑017‑03997‑y 28623312
     [Google Scholar]
  9. McInnesC.J. DamonI.K. SmithG.L. ICTV virus taxonomy profile: Poxviridae 2023.J. Gen. Virol.2023104510.1099/jgv.0.001849 37195882
     [Google Scholar]
  10. YangZ. GrayM. WinterL. Why do poxviruses still matter?Cell Biosci.20211119610.1186/s13578‑021‑00610‑8 34022954
     [Google Scholar]
  11. KugelmanJ.R. JohnstonS.C. MulembakaniP.M. Genomic variability of monkeypox virus among humans, Democratic Republic of the Congo.Emerg. Infect. Dis.201420223223910.3201/eid2002.130118 24457084
     [Google Scholar]
  12. DwivediS. YadavS.S. SinghM.K. ShuklaS. KhattriS. PantK.K. Pharmacogenomics of viral diseases.In: Omics for Personalized Medicine.Berlin, HeidelbergSpringerLink201310.1007/978‑81‑322‑1184‑6_28
     [Google Scholar]
  13. PatelV.M. PatelS.V. Epidemiological review on monkeypox.Cureus2023152e34653 36895541
     [Google Scholar]
  14. LiY. HouJ. SunZ. Monkeypox virus 2022, gene heterogeneity and protein polymorphism.Signal Transduct. Target. Ther.20238127810.1038/s41392‑023‑01540‑2 37460567
     [Google Scholar]
  15. BerthetN. Descorps-DeclèreS. BesombesC. Genomic history of human monkey pox infections in the Central African Republic between 2001 and 2018.Sci. Rep.20211111308510.1038/s41598‑021‑92315‑8 34158533
     [Google Scholar]
  16. BrennanG. StoianA.M.M. YuH. molecular mechanisms of poxvirus evolution.MBio2023141e01526e2210.1128/mbio.01526‑22 36515529
     [Google Scholar]
  17. LansiauxE. JainN. LaivacumaS. ReinisA. The virology of human monkeypox virus (hMPXV): A brief overview.Virus Res.202232219893210.1016/j.virusres.2022.198932 36165924
     [Google Scholar]
  18. GieryńskaM. Szulc-DąbrowskaL. StruzikJ. Orthopoxvirus Zoonoses—Do We Still Remember and Are Ready to Fight?Pathogens202312336310.3390/pathogens12030363 36986285
     [Google Scholar]
  19. PauliG. BlümelJ. BurgerR. Orthopox viruses: Infections in humans.Transfus. Med. Hemother.201037635136410.1159/000322101 21483466
     [Google Scholar]
  20. StanfordM.M. McFaddenG. KarupiahG. ChaudhriG. Immunopathogenesis of poxvirus infections: Forecasting the impending storm.Immunol. Cell Biol.20078529310210.1038/sj.icb.7100033 17228320
     [Google Scholar]
  21. KelleyC.F. KraftC.S. de ManT.J. The rectal mucosa and condomless receptive anal intercourse in HIV-negative MSM: Implications for HIV transmission and prevention.Mucosal Immunol.2017104996100710.1038/mi.2016.97 27848950
     [Google Scholar]
  22. DavidoB. D’anglejanE. JourdanJ. RobinaultA. DavidoG. Monkeypox 2022 outbreak: Cases with exclusive genital lesions.J. Travel Med.2022296taac07710.1093/jtm/taac077 35699601
     [Google Scholar]
  23. SongH. JosleynN. JanoskoK. Monkeypox virus infection of rhesus macaques induces massive expansion of natural killer cells but suppresses natural killer cell functions.PLoS One2013810e7780410.1371/journal.pone.0077804 24147080
     [Google Scholar]
  24. HajishengallisG. ReisE.S. MastellosD.C. RicklinD. LambrisJ.D. Novel mechanisms and functions of complement.Nat. Immunol.201718121288129810.1038/ni.3858 29144501
     [Google Scholar]
  25. ChenN. LiG. LiszewskiM.K. Virulence differences between monkeypox virus isolates from West Africa and the Congo basin.Virology20053401466310.1016/j.virol.2005.05.030 16023693
     [Google Scholar]
  26. LumF.M. Torres-RuestaA. TayM.Z. Monkeypox: Disease epidemiology, host immunity and clinical interventions.Nat. Rev. Immunol.2022221059761310.1038/s41577‑022‑00775‑4 36064780
     [Google Scholar]
  27. Al-MusaA. ChouJ. LaBereB. The resurgence of a neglected orthopoxvirus: Immunologic and clinical aspects of monkeypox virus infections over the past six decades.Clin. Immunol.202224310910810.1016/j.clim.2022.109108 36067982
     [Google Scholar]
  28. ZaeckL.M. LamersM.M. VerstrepenB.E. Low levels of monkeypox virus-neutralizing antibodies after MVA-BN vaccination in healthy individuals.Nat. Med.202329127027810.1038/s41591‑022‑02090‑w 36257333
     [Google Scholar]
  29. SammartinoJ.C. CassanitiI. FerrariA. Characterization of immune response against monkeypox virus in cohorts of infected patients, historic and newly vaccinated subjects.J. Med. Virol.2023955e2877810.1002/jmv.28778 37212258
     [Google Scholar]
  30. AsquithW. HuestonL. DwyerD. Characterizing the acute antibody response of monkeypox and MVA‐BN vaccine following an Australian outbreak.J. Med. Virol.2024961e2940710.1002/jmv.29407 38240403
     [Google Scholar]
  31. LiH. HuangQ.Z. ZhangH. The land-scape of immune response to monkeypox virus.EBioMedicine20238710442410.1016/j.ebiom.2022.104424 36584594
     [Google Scholar]
  32. ArndtW.D. CotsmireS. TrainorK. Evasion of the innate immune type I interferon system by monkeypox virus.J. Virol.20158920104891049910.1128/JVI.00304‑15 26246580
     [Google Scholar]
  33. EstebanD.J. NuaraA.A. BullerR.M.L. Interleukin-18 and glycosaminoglycan binding by a protein encoded by Variola virus.J. Gen. Virol.20048551291129910.1099/vir.0.79902‑0 15105546
     [Google Scholar]
  34. TakataM.A. Gonçalves-CarneiroD. ZangT.M. CG dinucleotide suppression enables antiviral defence targeting non-self RNA.Nature2017550767412412710.1038/nature24039 28953888
     [Google Scholar]
  35. NchiouaR. KmiecD. MüllerJ.A. SARS-CoV-2 is restricted by zinc finger antiviral protein despite preadaptation to the low-CpG environment in humans.MBio2020115e01930e2010.1128/mBio.01930‑20 33067384
     [Google Scholar]
  36. PengC. WyattL.S. Glushakow-SmithS.G. Lal-NagM. WeisbergA.S. MossB. Zinc-finger antiviral protein (ZAP) is a restriction factor for replication of modified vaccinia virus Ankara (MVA) in human cells.PLoS Pathog.2020168e100884510.1371/journal.ppat.1008845 32866210
     [Google Scholar]
  37. HudsonP.N. SelfJ. WeissS. Elucidating the role of the complement control protein in monkeypox pathogenicity.PLoS One201274e3508610.1371/journal.pone.0035086 22496894
     [Google Scholar]
  38. DwivediS. SamdariyaS. ChikaraG. GoelA. PandeyR.K. PareekP. Molecular biotechnology for diagnostics.Applied Molecular Biotechnology.Boca Raton, FloridaCRC Press201610.1201/b19543‑16
     [Google Scholar]
  39. ChowdhuryS.R. DattaP.K. MaitraS. Monkeypox and its pandemic potential: What the anaesthetist should know.Br. J. Anaesth.20221293e49e5210.1016/j.bja.2022.06.007 35803753
     [Google Scholar]
  40. DwivediS. Recent Advances in molecular diagnostic approaches for microbial diseases.Recent Advances in Microbiology.Hauppauge, New YorkNova Publishers2012
     [Google Scholar]
  41. DwivediS. PurohitP. MittalY. GuptaG. GoelA. VermaR.C. Genetic Engineering: Towards Gene Therapy and Molecular Medicine.Omics Technologies and Bio-Engineering.Massachusetts, United StatesAcademic Press2018507532 https://www.sciencedirect.com/science/article/pii/B9780128046593000221 10.1016/B978‑0‑12‑804659‑3.00022‑1
     [Google Scholar]
  42. DwivediS. PurohitP. MisraR. Diseases and molecular diagnostics: A step closer to precision medicine.Indian J. Clin. Biochem.201732437439810.1007/s12291‑017‑0688‑8 29062170
     [Google Scholar]
  43. CDC. Rapid diagnostic testing for response to the monkeypox outbreak — laboratory response network, United States, May 17– June 30,20222022Available From: https://www.cdc.gov/mmwr/volumes/71/wr/mm7128e1.htm
  44. VeeraraghavanV.P. BalajiJ.N. PrakashS. PrasharL. MonyU. SurapaneniK.M. Laboratory networking systems to tackle the spread of monkeypox virus – a need of the hour.Int. J. Surg.2023109216116210.1097/JS9.0000000000000148 36799837
     [Google Scholar]
  45. AlakunleE. MoensU. NchindaG. OkekeM.I. Monkeypox virus in Nigeria: Infection biology, epidemiology, and evolution.Viruses20201211125710.3390/v12111257 33167496
     [Google Scholar]
  46. GongQ. WangC. ChuaiX. ChiuS. Monkeypox virus: A re-emergent threat to humans.Virol. Sin.202237447748210.1016/j.virs.2022.07.006 35820590
     [Google Scholar]
  47. OlsonV.A. LaueT. LakerM.T. Real-time PCR system for detection of orthopoxviruses and simultaneous identification of smallpox virus.J. Clin. Microbiol.20044251940194610.1128/JCM.42.5.1940‑1946.2004 15131152
     [Google Scholar]
  48. KuleshD.A. LovelessB.M. NorwoodD. Monkeypox virus detection in rodents using real-time 3′-minor groove binder TaqMan® assays on the Roche LightCycler.Lab. Invest.20048491200120810.1038/labinvest.3700143 15208646
     [Google Scholar]
  49. LiY. OlsonV.A. LaueT. LakerM.T. DamonI.K. Detection of monkeypox virus with real-time PCR assays.J. Clin. Virol.200636319420310.1016/j.jcv.2006.03.012 16731033
     [Google Scholar]
  50. ArafY. NipaJ.F. NaherS. Insights into the transmission, host range, genomics, vaccination, and current epidemiology of the monkeypox virus.Vet. Med. Int.2024202411810.1155/2024/8839830 38836166
     [Google Scholar]
  51. GanapthyD. SekaranS. Rajamani SekarS.K. Monkeypox treatment options: Current status of antiviral drugs – a correspondence.Int. J. Surg.2023109356256310.1097/JS9.0000000000000147 37093094
     [Google Scholar]
  52. ShamimM.A. SatapathyP. PadhiB.K. Pharmacological treatment and vaccines in monkeypox virus: A narrative review and bibliometric analysis.Front. Pharmacol.202314114990910.3389/fphar.2023.1149909 37214444
     [Google Scholar]
  53. VoraS. DamonI. FulginitiV. Severe eczema vaccinatum in a household contact of a smallpox vaccinee.Clin. Infect. Dis.200846101555156110.1086/587668 18419490
     [Google Scholar]
  54. RussoA.T. GrosenbachD.W. ChinsangaramJ. An overview of tecovirimat for smallpox treatment and expanded anti-orthopoxvirus applications.Expert Rev. Anti Infect. Ther.202119333134410.1080/14787210.2020.1819791 32882158
     [Google Scholar]
  55. HalaniS. LeongD. WuP.E. Tecovirimat for monkeypox.CMAJ202219446E157310.1503/cmaj.221210 36442878
     [Google Scholar]
  56. SuzukiT. SaitoS. TsuzukiS. Protocol of Tecopox study: A multicentre, open-label, double-arm trial to evaluate the efficacy and safety of oral tecovirimat therapy for patients with smallpox or monkeypox.BMJ Open2023138e06955010.1136/bmjopen‑2022‑069550 37527886
     [Google Scholar]
  57. FDA. FDA approves the first drug with an indication for treatment of smallpox.2020Available From https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-indication-treatment-smallpox
  58. JayswalS. KakadiyaJ. A narrative review of pox: Smallpox vs monkeypox.Egypt. J. Intern. Med.20223419010.1186/s43162‑022‑00174‑0 36530575
     [Google Scholar]
  59. CD. Mpox treatment information for healthcare professionals.2024Available From: https://www.cdc.gov/poxvirus/mpox/clinicians/treatment.html
  60. LanierR. TrostL. TippinT. Development of CMX001 for the Treatment of Poxvirus Infections.Viruses20102122740276210.3390/v2122740 21499452
     [Google Scholar]
  61. BertranM. AndrewsN. DavisonC. Effectiveness of one dose of MVA–BN smallpox vaccine against mpox in England using the case-coverage method: An observational study.Lancet Infect. Dis.202323782883510.1016/S1473‑3099(23)00057‑9 36924787
     [Google Scholar]
  62. RizkJ.G. LippiG. HenryB.M. ForthalD.N. RizkY. Prevention and treatment of monkeypox.Drugs202282995796310.1007/s40265‑022‑01742‑y 35763248
     [Google Scholar]
  63. PetersenB.W. HarmsT.J. ReynoldsM.G. HarrisonL.H. Use of vaccinia virus smallpox vaccine in laboratory and health care personnel at risk for occupational exposure to orthopoxviruses — recommendations of the Advisory Committee on Immunization Practices (ACIP), 2015.MMWR Morb. Mortal. Wkly. Rep.2016651025726210.15585/mmwr.mm6510a2 26985679
     [Google Scholar]
  64. AliY. KhanA.A. AlanaziA.M. Identification of the myxobacterial secondary metabolites Aurachin A and Soraphinol A as promising inhibitors of thymidylate kinase of the Monkeypox virus.Mol. Divers.2024202410764x10.1007/s11030‑023‑10764‑x 38183513
     [Google Scholar]
  65. CDC. Mpox vaccine recommendations.2024Available From https://www.cdc.gov/poxvirus/mpox/vaccines/vaccine-recommendations. html
  66. SiegristC.M. KinahanS.M. SettecerriT. GreeneA.C. SantarpiaJ.L. CRISPR/Cas9 as an antiviral against Orthopoxviruses using an AAV vector.Sci. Rep.20201011930710.1038/s41598‑020‑76449‑9 33168908
     [Google Scholar]
  67. DenzlerK.L. BabasT. RippeonA. Attenuated NYCBH vaccinia virus deleted for the E3L gene confers partial protection against lethal monkeypox virus disease in cynomolgus macaques.Vaccine201129529684969010.1016/j.vaccine.2011.09.135 22001879
     [Google Scholar]
  68. IvashinaS.A. PoberezkinaD.Ia. Value of the immunological indicators in the study of the health status of the chemical industry workers.Zh. Mikrobiol. Epidemiol. Immunobiol.197798993 596027
     [Google Scholar]
  69. HuijserE GöpfertJ BrkicZ POS0189 Serum IFNα concentrations measured with single-molecule array technology in SJÖGREN’S Syndrome reflect blood interferon-stimulated gene expression.Ann Rheum Dis202180(Suppl. 1)3081910.1136/annrheumdis‑2021‑eular.2056
     [Google Scholar]
  70. Carbonell-BobadillaN. Soto-FajardoC. Amezcua-GuerraL.M. Patients with seronegative rheumatoid arthritis have a different phenotype than seropositive patients: A clinical and ultrasound study.Front. Med. (Lausanne)2022997835110.3389/fmed.2022.978351 36052337
     [Google Scholar]
  71. AliY. ImtiazH. TahirM.M. Fragment-Based Approaches Identified Tecovirimat-Competitive Novel Drug Candidate for Targeting the F13 Protein of the Monkeypox Virus.Viruses202315257010.3390/v15020570 36851785
     [Google Scholar]
  72. LedermanE.R. DavidsonW. GroffH.L. Progressive vaccinia: Case description and laboratory-guided therapy with vaccinia immune globulin, ST-246, and CMX001.J. Infect. Dis.201220691372138510.1093/infdis/jis510 22904336
     [Google Scholar]
  73. RussoA.T. BerhanuA. BiggerC.B. Co-administration of tecovirimat and ACAM2000™ in non-human primates: Effect of tecovirimat treatment on ACAM2000 immunogenicity and efficacy versus lethal monkeypox virus challenge.Vaccine202038364465410.1016/j.vaccine.2019.10.049 31677948
     [Google Scholar]
  74. Molero-AbrahamM. GluttingJ.P. FlowerD.R. LafuenteE.M. RecheP.A. EPIPOX: Immunoinformatic characterization of the shared T-Cell epitome between variola virus and related pathogenic orthopoxviruses.J. Immunol. Res.2015201511110.1155/2015/738020 26605344
     [Google Scholar]
  75. AfricaC.D.C. Outbreak brief 9: Monkeypox in Africa Union Member States.2022Available From: https://africacdc.org/disease-outbreak/outbreak-brief-9-monkeypox-in-africa-union-member-states/
  76. NyameJ. PunniyakottiS. KheraK. PalR.S. VaradarajanN. SharmaP. Challenges in the treatment and prevention of monkeypox infection; A comprehensive review.Acta Trop.202324510696010.1016/j.actatropica.2023.106960 37276922
     [Google Scholar]
  77. AlshahraniN.Z. MitraS. AlkuwaitiA.A. Medical Students’ perception regarding the re-emerging monkeypox virus: An institution-based cross-sectional study from Saudi Arabia.Cureus2022148e2806010.7759/cureus.28060 36127980
     [Google Scholar]
  78. MauryaC.K. MisraR. SharmaP. Novel stem cells and nucleic acid-based vaccine trials against viral outbreak: A systematic evaluation during COVID-2019 pandemic.Indian J. Clin. Biochem.202035439740910.1007/s12291‑020‑00907‑4 32837030
     [Google Scholar]
  79. PriyamvadaL. BurgadoJ. Baker-WagnerM. New methylene blue derivatives suggest novel anti-orthopoxviral strategies.Antiviral Res.202119110508610.1016/j.antiviral.2021.105086 33992710
     [Google Scholar]
  80. CaoS. RealegenoS. PantA. SatheshkumarP.S. YangZ. Suppression of poxvirus replication by resveratrol.Front. Microbiol.20178219610.3389/fmicb.2017.02196 29204136
     [Google Scholar]
  81. MuckerE.M. ShamblinJ.D. GoffA.J. Evaluation of virulence in cynomolgus macaques using a virus preparation enriched for the extracellular form of monkeypox virus.Viruses2022149199310.3390/v14091993 36146799
     [Google Scholar]
  82. DwivediS. AgrawalR. MisraR. AnjumS. KushwahaS.S. JoshiH.S. Biotechnology in primary healthcare and hospital management.Biotechnology in Healthcare.Massachusetts, United StatesAcademic Press202231910.1016/B978‑0‑323‑90042‑3.00012‑8
     [Google Scholar]
/content/journals/iddt/10.2174/0118715265309361240806064619
Loading
The Human Monkeypox Virus and Host Immunity: Emerging Diagnostic and Therapeutic Challenges
Infect. Disord. Drug Targets 25, E18715265309361 (2025); https://doi.org/10.2174/0118715265309361240806064619
/content/journals/iddt/10.2174/0118715265309361240806064619
/content/journals/iddt/10.2174/0118715265309361240806064619
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): adaptive immunity; diagnostics; genomics; host immunity; Human monkeypox virus; innate immunity; treatments

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test